IVL3001
IVL3001 is in Phase 1/2 for androgenetic alopecia, developed by Inventage Lab.
Finasteride as a monthly injection, so the daily tablet people forget becomes a clinic visit.
Nothing new since Mar 2022
- Developed by
- Inventage Lab
- Current phase
- Phase 1/2
- Mechanism
- 5α-reductase inhibitor
- Partners
- Daewoong Pharmaceutical
- Indications
- Androgenetic alopecia
- Also known as
- IVL-3001, finasteride long-acting injection
- Last public activity
- March 2022
- Copy last reviewed
- September 2026
- Record confidence
- Medium
A combined safety and early-efficacy study.
Stops testosterone being converted into DHT, the hormone that drives pattern hair loss.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
Finasteride loaded into PLGA microspheres for subcutaneous injection, releasing over a month; the mechanism is the one the tablet has had since 1997. CKD-843, the dutasteride depot in this register, is the same idea with the other molecule.
Why it matters
The Phase 1, published in Advances in Therapy in 2024, gave healthy men single doses of 12 to 36 mg against daily oral finasteride and found a flat plasma profile without the daily peaks, with monthly dosing modelled to match the tablet's DHT suppression. In December 2025 Korean press reported a Phase 2 filing with Australia's TGA for the monthly form, developed with Daewoong, with a Korean filing then planned for the first half of 2026. The registry classes the completed trial as Phase 1/2; no Phase 2 has appeared in a registry yet, and it will be recorded here when one lists it.
Development history
- Phase 1/2
First Phase 1/2 trial on record: NCT04945226 — A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
Inventage Lab., Inc. · n=40 · September 2021
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia — Peer-reviewed
- A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 — ClinicalTrials.gov
- 인벤티지랩, 남성형 탈모 치료제 'IVL3001' 글로벌 임상 2상 IND 신청 — Press, December 2025
Related programmes
Other programmes in the register with the same mechanism: 5α-reductase inhibitor.
Cite this page
Hair Pipeline, "IVL3001 — development record", hairpipeline.com/pipeline/ivl3001